Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

10 Nov 2018

• By Joseph Haas

scientists doing lab research on digital screen

Related Content

Gilead Pays Phenex $100m Milestone As NASH Candidate Progresses

06 Jan 2017

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

13 Jan 2017

Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

22 Mar 2017

Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate

17 Nov 2014

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

20 Apr 2018

Related Companies

Gilead Sciences, Inc.

Phenex Pharmaceuticals AG

Intercept Pharmaceuticals, Inc.

Novartis AG

Enanta Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.